OSI 906, also known as linsitinib, is an experimental drug candidate that inhibits the insulin receptor and insulin-like growth factor 1 receptor (IGF-1R). It is primarily used in cancer research for its ability to prevent tumor cell proliferation and induce apoptosis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing OSI 906?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Olodaterol
pharmaceutical raw material
Imetelstat
pharmaceutical raw material
7-Bromo-5-(6-methylpyridin-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
pharmaceutical raw material
Carfilzomib
pharmaceutical raw material
The international HS code for OSI 906 (CAS 867160-71-2) is 2933.49.
2933.49
2933 49 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
PKCDDUHJAFVJJB-UHFFFAOYSA-N
CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O
Sourcing OSI 906?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.